Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析

◆英語タイトル:Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH66532FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alnylam Pharmaceuticals Inc (ALNY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes therapeutics based on RNAi interference. The company’s marketed RNAi therapeutics include, Onpattro, is used in treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for treatment of acute hepatic porphyria, Oxlumo developed for treatment of primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in the US, Austria, Belgium, Bermuda, Canada, France, Germany, Italy, Japan, Taiwan, Portugal, Spain, Sweden, the Netherlands, Switzerland, Czech Republic, and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Apr 15,2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06,2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11,2021: Alnylam issues inaugural corporate responsibility summary
Feb 18,2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11,2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alnylam Pharmaceuticals Inc – Key Facts
Alnylam Pharmaceuticals Inc – Key Employees
Alnylam Pharmaceuticals Inc – Key Employee Biographies
Alnylam Pharmaceuticals Inc – Major Products and Services
Alnylam Pharmaceuticals Inc – History
Alnylam Pharmaceuticals Inc – Company Statement
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Alnylam Pharmaceuticals Inc – Business Description
Product Category: Product Revenue
Performance
Product Category: Revenue from Collaborations
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alnylam Pharmaceuticals Inc – Corporate Strategy
Alnylam Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Alnylam Pharmaceuticals Inc – Strengths
Alnylam Pharmaceuticals Inc – Weaknesses
Alnylam Pharmaceuticals Inc – Opportunities
Alnylam Pharmaceuticals Inc – Threats
Alnylam Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 15, 2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06, 2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11, 2021: Alnylam issues inaugural corporate responsibility summary
Feb 18, 2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Jan 10, 2021: Alnylam launches “Alnylam P⁵x25” strategy for planned transition to a top five biotech in market capitalization over next five years
Dec 21, 2020: Alnylam appoints Tolga Tanguler chief commercial officer and also announces new CEMEA, medical affairs, and compliance leaders
Dec 15, 2020: Alnylam announces 2021 product and pipeline goals and provides program updates at R&D Day
Dec 08, 2020: CENTOGENE and Alnylam Pharmaceuticals launch a new clinical program aimed at revolutionizing the diagnosis of hereditary transthyretin-related amyloidosis (“ATTRv”)
Dec 07, 2020: Alnylam issues 2nd Annual Patient Access Philosophy report highlighting broad access to the company’s approved therapies
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alnylam Pharmaceuticals Inc, Key Facts
Alnylam Pharmaceuticals Inc, Key Employees
Alnylam Pharmaceuticals Inc, Key Employee Biographies
Alnylam Pharmaceuticals Inc, Major Products and Services
Alnylam Pharmaceuticals Inc, History
Alnylam Pharmaceuticals Inc, Subsidiaries
Alnylam Pharmaceuticals Inc, Joint Venture
Alnylam Pharmaceuticals Inc, Key Competitors
Alnylam Pharmaceuticals Inc, Ratios based on current share price
Alnylam Pharmaceuticals Inc, Annual Ratios
Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1)
Alnylam Pharmaceuticals Inc, Interim Ratios
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hanwha Solutions Corp (009830):企業の財務・戦略的SWOT分析
    Summary Hanwha Solutions Corp (Hanwha Solutions), a subsidiary of Hanwha Corp, is a provider of chemicals, solar energy solutions and advanced industrial materials. The company is engaged in the production of inorganic chemical, plastic and polymer products which include chlorine and caustic soda, p …
  • Nuvo Pharmaceuticals Inc (NRI):企業の財務・戦略的SWOT分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly Nuvo Research Inc, is a healthcare company that offers portfolio of commercial products and pharmaceutical manufacturing capabilities. The company’s product portfolio includes pennsaid, heated lidocaine and tetracaine patches. Its products deliver dr …
  • The Coca-Cola Co:戦略・SWOT・企業財務分析
    The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report Summary The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SR Technics Holding:企業の戦略的SWOT分析
    SR Technics Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • GVK Power and Infrastructure Ltd (GVKPIL):企業の財務・戦略的SWOT分析
    GVK Power and Infrastructure Ltd (GVKPIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Abdullah Al-Othaim Markets Co.:企業の戦略・SWOT・財務分析
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Yanmar Co Ltd:企業の戦略的SWOT分析
    Yanmar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Dan Hotels Corporation Ltd:戦略・SWOT・企業財務分析
    Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Kodiak Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC, is a drug company that discovers and develops new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes its proprietary Bioc …
  • Aerojet Rocketdyne Holdings Inc:企業の戦略・SWOT・財務情報
    Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NTT DOCOMO Inc:企業の戦略・SWOT・財務分析
    NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report Summary NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Photocure ASA (PHO):企業の財務・戦略的SWOT分析
    Photocure ASA (PHO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Fujita Kanko Inc:企業の戦略・SWOT・財務情報
    Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report Summary Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Qatar Islamic Bank:企業の戦略・SWOT・財務分析
    Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report Summary Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sumitomo Corporation:企業の戦略・SWOT・財務分析
    Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • GEE Group Inc (JOB):企業の財務・戦略的SWOT分析
    Summary GEE Group Inc (GEE) is a provider of professional staffing and recruiting services. The company’s staffing services comprise temporary staffing services, professional placement services, and management services. It provides direct hire, contract, and contract-to-hire services in accounting, …
  • Daewoo Shipbuilding & Marine Engineering Co Ltd:戦略・SWOT・企業財務分析
    Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Cordis Corp:医療機器:M&Aディール及び事業提携情報
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆